Claim Missing Document
Check
Articles

Found 2 Documents
Search

Incidence of Peripheral Neuropathy in Major Beta-Thalassemia Patients at Hasan Sadikin General Hospital, Bandung, Indonesia Putri, Fanny Adhy; Gamayani, Uni; Lailiyya, Nushrotul; Panigoro, Ramdan
Cermin Dunia Kedokteran Vol 46, No 9 (2019): Neuropati
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (610.493 KB) | DOI: 10.55175/cdk.v46i9.416

Abstract

Bakground. Beta major thalassemia is the most common inherited blood disorder worldwide. It can lead to various neurological complications such as peripheral neuropathy. Toronto Clinical Neuropathy Score (TCNS) is helpful for peripheral neuropathy screening especially in diabetes mellitus. Objective. To investigate the prevalence of peripheral neuropathy in beta major thalassemia patient using Toronto Clinical Neuropathy Score (TCNS). Method. A descriptive study on beta major thalassemia patients aged more than 14 years who regularly underwent blood transfusions in Hasan Sadikin General Hospital Bandung, from July to August 2017. Normal TCNS values was < 4, mild neuropathy 5-7, moderate neuropathy 8-10 and severe neuropathy > 10. Results. Sixty subjects met the inclusion criteria, 48,3% were male with the mean (SD) age of 20,7 ± 7,6 years. Mean hemoglobin value was 6,7 ± 0,9 g/dL and median (IQR) blood ferritin serum was 2873 (1900-3859) μg/L. Thirty-two subjects had neuropathy; 19 (31,7%) with mild neuropathy and 13 (21,6%) with moderate neuropathy.Conclusion. The incidence of peripheral neuropathy in patients with thalassemia according to TCNS score is fairly high.Latar Belakang. Talasemia beta mayor adalah kelainan darah bawaan paling umum di dunia dan dapat menyebabkan berbagai komplikasi, salah satunya neuropati perifer. Toronto Clinical Neuropathy Score (TCNS) dapat digunakan untuk penilaian neuropati perifer yang disebabkan oleh berbagai penyakit sistemik. Objektif. Menyelidiki prevalensi neuropati perifer pada pasien talasemia beta mayor menggunakan Toronto Clinical Neuropathy Score (TCNS). Metode. Penelitian ini studi deskriptif skrining menggunakan TCNS pada pasien thalassaemia beta mayor berusia lebih dari 14 tahun yang secara teratur menjalani transfusi darah di Rumah Sakit Umum Hasan Sadikin Bandung, dari Juli hingga Agustus 2017. Nilai TCNS normal adalah <4, neuropati ringan 5-7, neuropati sedang 8-10 dan neuropati berat> 10. Hasil. Sebanyak 60 subjek memenuhi kriteria inklusi, 48,3% laki-laki dengan usia rata-rata (SD) 20,7 ± 7,6 tahun. Nilai hemoglobin rata-rata 6,7 ± 0,9 g / dL dan serum ferritin darah median (IQR) adalah 2873 (1900-3859) μg / L. Tiga puluh dua subjek memiliki neuropati; 19 (31,7%) neuropati ringan dan 13 (21,6%) neuropati sedang. Simpulan. Insiden neuropati perifer pada pasien dengan talasemia menurut skor TCNS cukup tinggi.
Plasma pTau181 dan Gejala Neuropsikiatri pada Demensia Alzheimer: Sebuah Studi Cross-Sectional Fadhilah, Nailatul; Syafrita, Yuliarni; Susanti, Restu; Indra, Syarif; Susanti, Lydia; Putri, Fanny Adhy
Journal of Pharmaceutical and Sciences JPS Volume 8 Nomor 4 (2025)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v8i4.1143

Abstract

Alzheimer’s disease is the leading cause of dementia, marked by progressive cognitive decline and neuropsychiatric disturbances collectively known as behavioral and psychological symptoms of dementia (BPSD). Plasma phosphorylated tau at threonine-181 (pTau181) has emerged as a minimally invasive biomarker of tau-related neurodegeneration, but its association with BPSD remains uncertain. This study investigated the relationship between plasma pTau181 levels and BPSD in Alzheimer’s dementia. An analytical observational study with a cross-sectional design was conducted in patients clinically diagnosed with predefined eligibility criteria. Plasma pTau181 concentrations were measured using enzyme-linked immunosorbent assay (ELISA), while BPSD was assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). Statistical analyses were performed to examine associations between plasma pTau181 and BPSD status. Plasma pTau181 levels ranged from 4.32 to 97.23 pg/mL, with a median plasma pTau181 level of 19.29 pg/mL (IQR: 11.81-25.05) in patients without BPSD and 20.67 pg/mL (IQR: 11.81-43.41) in those with BPSD. No significant differences in pTau181 levels were observed between patients with and without BPSD (p = 0.310). These findings suggest that plasma pTau181 may not be directly related to the presence of BPSD in Alzheimer’s dementia. While plasma pTau181 remains a promising biomarker of tau pathology, its predictive value for neuropsychiatric symptoms appears limited. Longitudinal studies are needed to explore its role in BPSD pathophysiology further.